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Abstract  25 
When the BRCA1 and BRCA2 tumour suppressor genes were identified in the early 26 
1990s, the immediate implications of mapping, cloning and delineating the sequence 27 
of these genes were that individuals in families with a BRCA gene mutation could be 28 
tested for the presence of a mutation and their risk of developing cancer predicted. 29 
Over time though, the discovery of BRCA1 and BRCA2 has had a much greater 30 
impact than many might have imagined. In this review, we discuss how the discovery 31 
or BRCA1 and BRCA2 has informed not only an understanding of the molecular 32 
processes that drive tumourigenesis, but has also reignited an interest in 33 
therapeutically exploiting loss of function alterations in tumour suppressor genes. 34 
  35 
  36 
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1. BRCA1 and BRCA2 – discovery, genetics and biology 37 
Globally, breast cancer is the most common cancer in women. Its familial form 38 
constitutes 5-10% of all breast cancers and has a dominant mode of inheritance and 39 
is characterised by earlier onset of disease, relative to breast cancer in the general 40 
population. Heterozygous germ-line mutations in either the BRCA1 or BRCA2 tumour 41 
suppressor genes are the most common genetic cause of familial breast cancer, and 42 
were identified as breast cancer susceptibility genes in the 1990s through linkage 43 
analysis in families with the disease (Futreal, et al. 1994), (King 2014), (Miki, et al. 44 
1994), (Wooster, et al. 1995), (Tavtigian, et al. 1996). BRCA1 and BRCA2 mutations 45 
are found in 25% -28% of familial breast cancers and mutation carriers have a 46 
lifetime risk of 40-87% for developing breast cancer by the age of 70. Mutation 47 
carriers also have a lifetime risk of 45-60% (BRCA1 mutation carriers) or 11-35% 48 
(BRCA2 mutation carriers) for developing ovarian cancer (Ford, et al. 1998; King, et 49 
al. 2003). Other types of cancers also found in BRCA1 and BRCA2 mutation carriers 50 
include pancreatic and prostate cancers (Antoniou, et al. 2003; Breast Cancer 51 
Linkage 1999; Edwards, et al. 2003; King et al. 2003; Ozcelik, et al. 1997; van 52 
Asperen, et al. 2005). Although most familial BRCA1 or BRCA2 mutations are 53 
inherited as heterozygous mutations, rare, biallelic germ-line mutations do occur in 54 
patients with Fanconi anemia (Domchek, et al. 2013; Howlett, et al. 2002; Meyer, et 55 
al. 2014; Sawyer, et al. 2015). Furthermore, in addition to germ-line mutations in 56 
these genes, somatic BRCA1 and BRCA2 mutations are also found in breast, 57 
prostate, ovarian and pancreatic cancers, as is somatic hypermethylation of the 58 
BRCA1 gene promoter. An analysis of tumours from individuals with BRCA1 or 59 
BRCA2 mutations indicates that the wildtype allele is generally lost (Collins, et al. 60 
1995; Futreal et al. 1994; Gudmundsson, et al. 1995), suggesting that loss of 61 
heterozygosity at the BRCA1 and BRCA2 loci appears to be an important event for 62 
tumourigenesis. 63 
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 64 
Both BRCA1 and BRCA2 are very large genes, which display limited sequence 65 
homology to each other. BRCA1 is comprised of 24 exons that translate to a 1863 66 
amino acid protein with a RING domain with E3 ubiquitin ligase activity, a coiled-coil 67 
domain in the largely unstructured central region important for binding with another 68 
tumour suppressor protein, PALB2, and BRCT (BRCA1 carboxy terminal) repeats 69 
important for interaction with phosphorylated proteins (Brzovic, et al. 2001; Sy, et al. 70 
2009; Wu, et al. 1996; Xia, et al. 2006; Zhang, et al. 2009b). BRCA2 is comprised of 71 
27 exons that translate to a 3418 amino acid protein that includes amino-terminal 72 
BRC repeats, which mediate binding of BRCA2 to PALB2 and the DNA recombinase 73 
RAD51, a central DNA binding domain, and nuclear localization and RAD51 control 74 
domains at the carboxy-terminus (Sharan, et al. 1997; Wong, et al. 1997; Yang, et al. 75 
2002).  76 
 77 
Small insertions/deletions (in-dels) or nonsense mutations leading to truncations are 78 
the most common BRCA gene mutation type observed in cancer patients. There are 79 
at least 1790 distinct mutations, polymorphisms and variants that have been 80 
identified in BRCA1 to date and over 2000 in BRCA2 according to the Breast Cancer 81 
information Core (BIC) and ClinGen. Mutations are distributed across the entire 82 
coding sequence for both genes with over 50% of observed mutations being private 83 
to particular individuals. In addition to known pathogenic mutations, there are a large 84 
number of missense, in-frame deletion and silent mutations known as “variants of 85 
unknown significance” which have unclear pathogenic potential, making clinical 86 
interpretation of genetic testing difficult in cancer patients harboring these. 87 
 88 
Breast tumours in BRCA1 mutation carriers tend to have a basal-like transcriptional 89 
signature and more often than not exhibit a “triple negative” phenotype, lacking 90 
expression of the estrogen and progesterone receptors and lacking amplification of 91 
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the ERBB2 (HER2) oncogene (Foulkes, et al. 2003). This triple negative phenotype 92 
precludes the use of targeted estrogen receptor-based or ERBB2-specific therapies 93 
and in general, BRCA1 mutant breast cancers are treated with traditional genotoxic 94 
chemotherapy agents. In contrast, breast tumours in BRCA2 mutation carriers tend 95 
to better reflect the hormone receptor and ERBB2 status of breast cancers in the 96 
non-BRCA mutant population (Jonsson, et al. 2010; Waddell, et al. 2010).  97 
 98 
2. BRCA1 and BRCA2 functions in DNA repair and replication fork 99 
protection 100 
Tumourigenesis occurs in the absence of BRCA1 and BRCA2 as both proteins play 101 
important roles in the repair of DNA double-strand breaks (DSBs) (Moynahan and 102 
Jasin 2010) and the stability of replication forks. DSBs, the most toxic type of DNA 103 
lesions, can be catastrophic for the cell if left unrepaired as they compromise the 104 
double helix structure of DNA. The two main methods of DSB repair are the error-105 
prone non-homologous end-joining (NHEJ) pathway and the error-free homologous 106 
recombination (HR) pathway. NHEJ, used predominantly in the G1 phase of the cell 107 
cycle, can result in loss of genetic information proximal to the DSB site. In contrast, 108 
HR, active during S and G2 phases, uses homologous sequence from a sister 109 
chromatid for error-free repair of DSBs. In HR, after the initial detection of the DSB, 110 
the broken DNA ends are enzymatically resected to generate 3’ single-stranded DNA 111 
(ssDNA). The ssDNA is coated by the Replication Protein A (RPA) complex, which is 112 
then replaced by the RAD51 recombinase. The binding of multiple RAD51 molecules 113 
onto ssDNA enables strand invasion, where ssDNA from the damaged DNA site 114 
invades the double helix of intact DNA, a process that facilitates the identification of a 115 
homologous DNA sequence that is used as a template for DNA repair across the 116 
break site. Efficient resolution of the resulting intermediates completes the process 117 
with the genetic integrity of broken DNA restored.  118 
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 119 
BRCA1 and BRCA2 play key roles in HR. BRCA1 is required for CtIP-mediated 120 
resection of DSBs to generate single-stranded DNA (ssDNA) which is coated by the 121 
RPA complex (Chen, et al. 2008; Yu and Baer 2000). BRCA1-mediated resection is 122 
a key step in committing to repair by HR as opposed to the error-prone NHEJ 123 
pathway (Kass and Jasin 2010). CDK-phosphorylated CtIP protein binds BRCA1 124 
BRCT repeats, is localised to the DSB and mediates resection through the MRN 125 
(MRE11-RAD50-NBS1) complex (Chen et al. 2008; Sartori, et al. 2007; Wong, et al. 126 
1998; Yu, et al. 1998). In addition to CtIP localization to DSBs, BRCA1 also 127 
counteracts 53BP1 function, and in doing so impairs NHEJ (Bouwman, et al. 2010; 128 
Bunting, et al. 2010). Additionally, both BRCA1 and BRCA2, bridged by PALB2, are 129 
required for the recruitment of the DNA recombinase RAD51 to damaged DNA, 130 
where it forms a nucleoprotein complex (or “filament”) with ssDNA that mediates 131 
strand invasion (Sy et al. 2009; Tischkowitz and Xia 2010; Xia et al. 2006; Zhang, et 132 
al. 2009a; Zhang et al. 2009b). BRCA2 is not only required for localization of RAD51 133 
to RPA-coated DNA but also for stabilizing the RAD51 nucleofilament that is formed 134 
by blocking RAD51-mediated ATP hydrolysis.  135 
 136 
When the progression of replication forks is halted (replication fork stalling), which 137 
can be caused by a variety of factors including damaged DNA lesions being 138 
encountered by the replication fork or the relative absence of the requisite 139 
nucleotides, preventing the disintegration or collapse of the fork structure is key to 140 
the continued fitness of cells. One of the molecular events that challenges fork 141 
stability in this setting is the activity of the nuclease MRE11, which if not tightly 142 
controlled, degrades newly synthesised (nacent) DNA at the replication fork, 143 
potentially forcing fork collapse. In addition to their roles in DSB repair, BRCA1 and 144 
BRCA2 prevent the degradation of nascent DNA at stalled replication forks 145 
(Pathania, et al. 2014; Schlacher, et al. 2011; Schlacher, et al. 2012). For example, 146 
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Schlacher and colleagues found using single-molecule DNA fibre analysis that once 147 
replication forks are stalled with hydroxyurea (HU), tracts of nascent DNA produced 148 
prior to fork stalling are degraded in the absence of BRCA2 by MRE11. This 149 
protection of nascent DNA at replication forks appears to be mediated by a 150 
conserved C-terminal region in BRCA2 that stabilises RAD51 nucleoprotein filaments 151 
but is not required for RAD51 loading or homologous recombination per se 152 
(Schlacher et al. 2011). Using Brca1-deficient embryonic stem (ES) cells, Schlacher 153 
and colleagues later found that Brca1 also prevents fork degradation by MRE11 154 
(Schlacher et al. 2012). 155 
 156 
The loss of DNA repair and fork stability functions of BRCA1 and BRCA2 are likely 157 
causes of the genomic instability seen in BRCA1 or BRCA2 mutant tumours. Cells 158 
deficient in either protein have been shown to have reduced efficiency of HR 159 
(Moynahan, et al. 2001a; Moynahan, et al. 2001b). BRCA1/2-deficient cells also 160 
exhibit spontaneous and DNA-damage induced genetic instability, which 161 
subsequently contributes to tumourigenesis. Additionally, BRCA1/2-deficient cells are 162 
sensitive to DNA damaging agents, especially those that form crosslinks on DNA 163 
such as cisplatin (Narod 2010). This particular phenotype has been exploited in the 164 
clinic to treat BRCA-deficient tumours. In fact, cisplatin and its derivative, carboplatin, 165 
have been shown to be particularly effective in treatment of BRCA1 and BRCA2-166 
associated cancers, particularly in ovarian cancers (Boyd, et al. 2000; Cass, et al. 167 
2003; Chetrit, et al. 2008; Tan, et al. 2008; Vencken, et al. 2011). However, 168 
chemoresistance to platinum compounds is a very significant clinical problem and 169 
has a negative impact on patient survival. Therefore, identification of additional drugs 170 
that can effectively treat HR-deficient cancers is essential. 171 
 172 
  173 
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3. Therapeutic exploitation of BRCA gene defects with PARP inhibitors 174 
 175 
The intricate dissection of BRCA1 and BRCA2 function, and in particular the 176 
discovery that these tumour suppressor proteins were required for effective HR, 177 
made a significant impact upon the discovery and mechanistic understanding of 178 
therapeutic approaches that target BRCA1 or BRCA2 (BRCA1/2) gene mutant 179 
cancers. To date, the majority of agents proposed to selectively inhibit BRCA1/2 180 
mutant tumour cells likely do so by causing the stalling and collapse of DNA 181 
replication forks. Specifically, these agents cause replication fork damage that 182 
requires HR for repair (Figure 2). In the absence of BRCA1 or BRCA2 gene function, 183 
and therefore functional HR, tumour cells most likely attempt to repair replication 184 
forks via non-HR forms of DNA repair; these alternative repair strategies cause large 185 
scale chromosomal abnormalities which ultimately impair the fitness of cells and 186 
induce cell death. Early evidence of this phenomenon was suggested by work 187 
illustrating the sensitivity of BRCA gene defective cells to platinum salts (Bartz, et al. 188 
2006; Evers, et al. 2008; Fedier, et al. 2003) or topoisomerase inhibitors such as 189 
camptothecin (Rahden-Staron, et al. 2003). Platinum salts most likley stall replication 190 
forks by causing intra- and interstrand crosslinks in DNA through covalent interaction 191 
with nucleophilic N-7 sites on purine residues (Sikov 2015); these “lesions” within the 192 
DNA structure prevent normal unwinding of the DNA double helix prior to replication 193 
(Figure 2, (Sikov 2015)). DNA topoisomerase enzymes bind DNA and unwind its 194 
helical structure (Champoux 2001), a prerequistite for multiple processes such as 195 
DNA replication, transcription, recombination and chromatin remodeling (Champoux 196 
2001); topoisomerase inhibitors (also known as topo-poisons) such as camptothecin, 197 
fix or “trap” topoisomase on DNA (Lord and Ashworth 2012; O'Connell, et al. 2010). 198 
Presumably, this trapped form of topoisomerase provides a bulky structure which 199 
prevents the progression of the replication fork (Figure 2, (O'Connell et al. 2010)).  200 
 201 
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In in vitro tissue culture models at least, platinum salts and topoisomerase inhibitors 202 
selectively target BRCA1/2 gene mutant tumour cells, compared to cells with “wild 203 
type” function, but still have relatively profound inhibitory effects on wild type cells 204 
(Evers et al. 2008). Conversely, work from two teams in 2005, suggested that small 205 
molecule inhibitors of the DNA repair enzyme, poly (ADP-ribose) polymerase (PARP) 206 
caused profound cell inhibitory effects in BRCA1 (Farmer, et al. 2005) or BRCA2 207 
mutant (Bryant, et al. 2005; Farmer et al. 2005) tumour cells but had minimal effects 208 
in wild type cells with functional HR. PARP1, is an enzyme that uses β-NAD+ as a 209 
co-factor to synthesise poly (ADP-ribose) chains (PAR) on target proteins and has a 210 
known role in the repair of single strand DNA breaks (breaks in one strand of the 211 
DNA double helix) (Hottiger, et al. 2010). At the time, it was thought that the inhibition 212 
of PARP activity might cause an accumulation of DNA damage that requires HR for 213 
its repair (Bryant et al. 2005; Farmer et al. 2005). Subsequently, this hypothesis has 214 
been refined by data suggesting that the key cytotoxic DNA lesion in PARP inhibitor 215 
exposed tumour cells is PARP “trapped” on DNA (Figure 2, (Murai, et al. 2012; 216 
Murai, et al. 2014)), a mechanism reminiscent of that used to explain the BRCA 217 
selectivity of topoisomerase inhibitors. PARP binds damaged DNA and then initiates 218 
a series of PARylation events; one of these events is autoPARylation (PARylation of 219 
PARP itself), which causes the release of PARP once its role in the initial phase of 220 
DNA repair is complete (Murai et al. 2012). It seems possible that some catalytic 221 
inhibitors of PARP impair autoPARylation, thus trapping PARP on the double helix 222 
where it is able to stall and collapse replication forks (Figure 2).  223 
 224 
A number of years after the pre-clinical observation of PARP inhibitor/BRCA gene 225 
synthetic lethality, clinical trials, including those which studied breast cancer patients, 226 
confirmed the potential of PARP inhibitors as treatments for BRCA gene mutant 227 
cancers. Although these trials have recently been reviewed in detail elsewhere 228 
(Balmana, et al. 2011; Livraghi and Garber 2015; Lord, et al. 2015) the key trials can 229 
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be summarised as follows: 230 
 231 
3.1 Early phase 1 trials show sustained anti-tumour responses in germ-line 232 
BRCA mutant cancers. Although the first-in-human PARP inhibitor clinical trial 233 
assessed the safety of rucaparib (Pfizer), olaparib (aka AZD2281, Lynparza, 234 
KuDOS/AZ) was the first PARP inhibitor to be formally assessed in BRCA1/2 gene 235 
mutant patients. In a Phase 1 clinical trial of olaparib (Fong, et al. 2009) 60 patients 236 
were treated with 400 mg twice daily olaparib, 19 of whom had germ-line mutations 237 
in either BRCA1 or BRCA2; in this subset of BRCA1/2 gene mutant patents, 63% 238 
exhibited a clinical benefit from olaparib treatment, as defined by radiological and/or 239 
tumour marker responses or disease stabilization for a period greater than 4 months 240 
(Fong et al. 2009). Even though dose limiting myelosuppression and central nervous 241 
system side effects were seen in some patients, many of the sustained anti-tumour 242 
responses were not associated with the deleterious side effect profile normally 243 
associated with classical chemotherapy (Fong et al. 2009). On the basis of these 244 
promising results, the same phase I trial was subsequently expanded to include a 245 
total of 50 germline BRCA1/2 mutant carriers with ovarian, primary peritoneal or 246 
fallopian tube carcinoma; here an overall response rate (ORR) of 40% and a disease 247 
control rate (DCR) of 46% was observed (Fong, et al. 2010). In a retrospective 248 
analysis of this study, a significant correlation between a good response to prior 249 
platinum salt treatment and subsequent therapeutic response to olaparib was seen 250 
(Fong et al. 2010). One explanation for this correlation is that both platinum salts and 251 
PARP inhibitors both stall replication forks and require HR for the repair of the 252 
subsequent DNA lesions caused (Figure 2).  253 
 254 
3.2 Key phase 2 clinical trials in germ-line or somatic BRCA mutated cancers. 255 
The promising results from this Phase I clinical study prompted two Phase 2 clinical 256 
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trials investigating single-agent olaparib in patients with BRCA gene mutant 257 
chemotherapy-resistant breast (Tutt, et al. 2010) or ovarian cancers (Audeh, et al. 258 
2010). These trials, which used either a 400 mg or 100 mg twice daily treatment 259 
regimen, established an ORR of 33% in ovarian cancer patients in the 400 mg twice 260 
daily treatment schedule and 13% of the 100 mg twice daily group, with a median 261 
progression-free survival (PFS) of 5.8 months and 1.9 months respectively (Audeh et 262 
al. 2010). Similar response rates were observed in the breast cancer cohort, where a 263 
response rate (RR) of 22% was seen in the 100 mg twice daily cohort (PFS 3.8 264 
months), whereas a RR of 41% was observed in the cohort receiving a higher dose 265 
of olaparib (PFS 5.7 months) suggesting that the higher dose was essential in order 266 
to achieve a maximal clinical response.  267 
 268 
As discussed later, many sporadic ovarian serous and non-familial triple negative 269 
breast cancers display many of the molecular and histopathological features found in 270 
germ-line BRCA1/2 gene mutant tumours, which are often driven by somatic 271 
mutations in BRCA1, BRCA2 and other HR-modifying genes, a concept termed 272 
‘BRCAness’ (Turner, et al. 2004). On this basis, olaparib was also assessed as a 273 
monotherapy in sporadic cancers thought to display the BRCAness phenotype, 274 
namely high-grade serous ovarian cancer (HGSOvCa) and triple negative breast 275 
cancers (described earlier). In patients with HGSOvCa, both BRCA1/2 gene mutant 276 
and non-mutant patients demonstrated a number of sustained therapeutic responses 277 
to olaparib, a number of which were also associated with prior platinum sensitivity 278 
(Gelmon, et al. 2011). In triple negative breast cancer patients, those with BRCA1/2 279 
gene mutations exhibited a higher frequency of disease stabilization in response to 280 
olaparib treatment than those without BRCA1/2 gene mutations (63% versus 13%), 281 
but unlike in the ovarian cancer cohort, no sustained responses were achieved in 282 
either the BRCA1/2-mutant or non-mutant patients (Gelmon et al. 2011). Alongside 283 
these studies, olaparib was assessed as a maintenance therapy (i.e. a therapy used 284 
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to reduce disease recurrence after chemotherapy) in patients with HGSOvCa who 285 
had previously received carboplatin, a platinum salt chemotherapy ((Ledermann, et 286 
al. 2012) NCT00753545, Study 19). In this study, 136 patients received olaparib after 287 
chemotherapy, with 129 receiving a placebo instead. An early analysis of this trial 288 
suggested that when used as a maintenance monotherapy, olaparib significantly 289 
improved PFS, and time to first and second subsequent therapy or death compared 290 
to the use of a placebo in the maintenance setting, with BRCA1/2 mutant patients (be 291 
it germ-line or somatic) in the trial deriving the greatest benefit from olaparib. 292 
However, an effect on OS in either BRCA1/2 gene mutant or non- BRCA1/2 gene 293 
mutant patients was not seen (Ledermann, et al. 2014). Nevertheless, the 294 
improvements in PFS were sufficient to warrant an approval by the FDA and EMA for 295 
olaparib as a maintenance monotherapy in HGSOv cancer characterized by 296 
BRCA1/2 gene mutation, making this PARP inhibitor not only the first synthetic lethal 297 
treatment for cancer to be approved but also the first treatment for an inherited 298 
cancer (Kim, et al. 2015). A retrospective analysis of data from study 19, conducted 299 
after 77% of the patients had died, has now shown an overall survival benefit from 300 
olaparib maintenance monotherapy; in the BRCA mutant patients, this OS benefit 301 
was most pronounced (median OS 34.9 months for olaparib vs. 30.2 months for 302 
placebo, Hazard Ratio (HR) of 0.62), but was also seen in the entire dataset, which 303 
included both BRCA1/2 mutant and non-BRCA1/2 mutant patients (OS 29.8 months 304 
(olaparib) vs. 27.8 (placebo), HR 0.73) (Ledermann JA 2016). 305 
 306 
Additional clinical trials observed responses to olaparib in patients with BRCA1/2 307 
mutations in a spectrum of other BRCA1/BRCA2-associated cancers including 308 
pancreatic and prostate cancers (Kaufman, et al. 2015). Notable amongst these 309 
studies has been the TO-PARP phase II clinical trial assessing the efficacy of 310 
olaparib in men with metastatic, castration-resistant prostate cancer (Mateo, et al. 311 
2015). Out of 49 patients whom all had prior treatment (docetaxel, the androgen 312 
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synthesis inhibitor abiraterone or the androgen receptor inhibitor enzalutamide) and 313 
received oral olaparib at 400mg twice daily, 14 showed a response to olaparib; seven 314 
of these patients harboured BRCA2 defects and four exhibited tumour specific ATM 315 
defects, raising the possibility that other genes involved in HR, such as ATM, might 316 
also be good predictive biomarkers of olaparib response (Mateo et al. 2015). On the 317 
basis of this study, olaparib has now been given breakthrough status in prostate 318 
cancer, and an expansion of the TO-PARP trial to a larger number of patients with 319 
HR gene defects is now underway.  320 
Although, not all PARP inhibitor trials have delivered such positive results (Lord et al. 321 
2015), the clinical responses in the phase 2 trials described above, alongside the 322 
favourable side-effect profile of PARP inhibitors such as olaparib, talazoparib, 323 
rucaparib, niraparib and veliparib, has provided the impetus for initiating a series of 324 
phase III trials, including those in breast cancers. It is expected that within a few 325 
years, the data from these trials will provide some of the definitive information that 326 
could support or refute the case for using PARP inhibitors in cancers other than 327 
HGSOv cancer. 328 
 329 
4. Additional BRCA directed therapy  330 
As described above, in addition to PARP inhibitors, a number of conventional 331 
chemotherapies routinely used in the management of cancer might also provide an 332 
approach to targeting BRCA1/2 mutant tumours. These include platinum agents, 333 
topoisomerase I inhibitors (topotecan and camptothecin), topoisomerase II inhibitors 334 
(doxorubicin and etoposide) described above but also nucleoside analogous such as 335 
gemcitabine which prevents DNA synthesis when incorporated into DNA by 336 
preventing chain elongation during DNA replication (Gandhi, et al. 1996; Lord and 337 
Ashworth 2016). The common mechanism of action of these agents is that they can 338 
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stall the normal progression of replication forks and likely require BRCA and HR 339 
function for the repair of the DNA lesions they cause. These agents have been 340 
assessed both pre-clinically (Bartz et al. 2006; Fedier et al. 2003; Rahden-Staron et 341 
al. 2003) and clinically and have shown selectivity in BRCA1/2 defective 342 
backgrounds (Kilburn and Group 2008; Silver, et al. 2010). 343 
 344 
One of characteristics of BRCA1/2 mutant tumours is an elevated mutational load, 345 
compared to non- BRCA1/2 mutant tumours, a likely effect of defective HR. Clinical 346 
responses to immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 347 
antibodies have previously been associated with hypermutated cancers, including 348 
lung carcinomas and melanomas; it seems possible that similar approaches could be 349 
used to target BRCA mutant tumours. To investigate this, Strickland and colleagues 350 
recently predicted neoantigen load in BRCA1/2-mutated HGSOv tumours and found 351 
that this was elevated compared to tumours without HR gene defects, as were the 352 
presence of CD3+ and CD8+ tumour infiltrating lymphocytes and PD-1 and PD-L1 353 
expression in tumour-associated immune cells (Strickland, et al. 2016). Such an 354 
analysis therefore supports the clinical assessment of combinations of PARP 355 
inhibitors with PD-L1 inhibitors in breast and ovarian cancers (eg NCT02484404 - 356 
(Lee J 2016)), as does data from a pre-clinical study illustrating the efficacy of an 357 
anti-CTLA4 antibody in combination with the PARP inhibitor veliparib in a mouse 358 
model carrying a Brca1 mutant tumour (Higuchi, et al. 2015). 359 
 360 
5. Drug resistance in a BRCA mutant setting   361 
Though PARP inhibitors have shown to be useful for the treatment of BRCA1/2-362 
associated cancers, PARP inhibitor resistance is likely to be a major obstacle to the 363 
overall effectiveness of treatment (Fong et al. 2009; Tutt et al. 2010). PARP inhibitor 364 
resistance, in BRCA1 or BRCA2 mutant cancers, can occur due to reversal of 365 
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synthetic lethality by several mechanisms including restoration of DSB repair by HR, 366 
loss of PARP1 expression, loss of 53BP1 expression and upregulation of PARP 367 
inhibitor efflux from cells (Figure 3).  368 
 369 
5.1 Restoration of BRCA1/2 function as a mechanism of PARP inhibitor 370 
resistance 371 
We and others hypothesized that restoration of HR may be able to reverse 372 
chemosensitivity to DNA damaging drugs in BRCA1/2-deficient cells based on the 373 
observation that spontaneously occurring secondary genetic alterations could 374 
compensate for the initial disease causing mutations in some patients with Fanconi 375 
anemia (FA), including reversal of DNA damaging agent sensitivity in patient cells 376 
(Hirschhorn 2003; Ikeda, et al. 2003; Wiegant, et al. 2006). We hypothesized that 377 
acquired secondary intragenic BRCA1 or BRCA2 mutations may reverse the effect of 378 
the initial disease-causing BRCA1/2 mutations in tumours and result in resistance to 379 
PARP inhibitors and DNA crosslinking drugs such as cisplatin and carboplatin 380 
(Edwards, et al. 2008; Sakai, et al. 2009; Sakai, et al. 2008; Swisher, et al. 2008).  381 
 382 
Evidence for secondary BRCA1/2 mutations as a method of reversing PARP 383 
inhibitor-related synthetic lethality was first demonstrated in several in vitro and in 384 
vivo drug-selected BRCA2 mutated cell lines (Edwards et al. 2008; Sakai et al. 2009; 385 
Sakai et al. 2008). PARP inhibitor- or cisplatin-selected clones of the pancreatic 386 
cancer cell line CAPAN-1 (BRCA2.6147delT) and ovarian cancer cell line PEO1 387 
(BRCA2.5193C>G) acquired secondary BRCA2 mutations that restore the open 388 
reading frame and express functional BRCA2 protein (Edwards et al. 2008; Sakai et 389 
al. 2009; Sakai et al. 2008). PARP inhibitor-resistant clones had internal insertions or 390 
deletions in the BRCA2 gene that eliminated the truncating effect of the parental 391 
c.6147delT mutation in CAPAN-1 cells and changed the nonsense mutation in PEO1 392 
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cells to a missense mutation. PEO4 ovarian cancer cells derived from the same 393 
patient as PEO1 cells, after the onset of clinical resistance, were resistant to both 394 
PARP inhibitor and cisplatin as a result of a secondary BRCA2 mutation that 395 
converts the parental nonsense mutation, p.Y1655X, to a silent mutation p.Y1655Y. 396 
The same silent mutation was also found in the drug resistant tumour sample from 397 
the same patient.  398 
 399 
The restored BRCA2 proteins in CAPAN-1, PEO1 and PEO4 cells are functional as 400 
evidenced by the restoration of ionizing radiation induced RAD51 foci formation, 401 
reduced DNA damage-induced chromosomal aberrations and cross-resistance to 402 
cisplatin. Non-BRCA2-restored clones of CAPAN-1 or PEO1 had neither secondary 403 
BRCA2 mutations nor restoration of damage induced RAD51 foci formation. 404 
Importantly, depletion of BRCA2 by siRNA reversed the drug resistance in BRCA2-405 
restored clones and ectopic expression of the mutant BRCA2 proteins found in 406 
resistant clones led to drug resistance in BRCA2-deficient backgrounds. 407 
 408 
Although the majority of pre-clinical studies identified mutations in BRCA1, and not 409 
BRCA1, that were associated with therapy resistance, several clinical studies have 410 
demonstrated that this is an effect that likely operates for both of the tumour 411 
suppressor genes. Norquist et al evaluated PARP inhibitor response in 412 
cisplatin/carboplatin-resistant ovarian tumours from patients with BRCA1 or BRCA2 413 
mutations (Norquist, et al. 2011). Of the three non-BRCA1/2-restored tumours, two 414 
showed complete response to PARP inhibitor and one showed a partial response. As 415 
expected, two of the three BRCA1/2-restored tumours with secondary BRCA1/2 416 
mutations did not show response as the disease progressed presumably due to 417 
restored HR, while the third showed partial response (Norquist et al. 2011).  418 
 419 
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In another study, Barber et al found evidence of secondary BRCA2 mutations in two 420 
PARP inhibitor-resistant tumours that were not present in matched treatment naïve 421 
tumour samples from the same patients (Barber, et al. 2013). A breast tumour from a 422 
male carrying the BRCA2c.9106C>T nonsense mutation, had acquired a secondary 423 
mutation that changed the nonsense (p.Q2960X) to a missense (p.Q2960E) 424 
mutation. The second observation was a high grade serous ovarian carcinoma from 425 
a patient carrying the BRCA2c.4705_4708delGAAA mutation who was previously 426 
treated for breast cancer. In this case, the BRCA2 open reading frame was restored 427 
as a result of a larger deletion, BRCA2c.4697_4709delAAATACTGAAAG, which 428 
encompassed the germline BRCA2 deletion mutation. Though not formally tested, 429 
both secondary BRCA2 mutations likely restore at least partially functional BRCA2 430 
protein that cancels PARP inhibitor-associated synthetic lethality (Barber et al. 2013). 431 
 432 
In an Australian study, whole genome sequencing and analysis of high grade serous 433 
ovarian carcinomas revealed five individuals with platinum resistant disease who had 434 
secondary BRCA1/2 mutations out of a total of ten patients analysed who had 435 
germline BRCA1/2 mutations (Patch, et al. 2015). One of the two patients, whose 436 
tumour was also cross-resistant to PARP inhibitor, had at least 12 distinct secondary 437 
deletion mutations in BRCA2 identified from multiple metastatic sites. The second 438 
patient had two distinct secondary BRCA1 mutations that changed the germline 439 
nonsense mutation to missense mutations in platinum-resistant cells. 440 
 441 
A recent study by Jonkers and colleagues has also provided strong evidence for 442 
BRCA1-restoration as an important mechanism for PARP inhibitor and cisplatin 443 
resistance in BRCA1-deficient, triple negative breast cancer (Ter Brugge, et al. 444 
2016). The analysis of patient derived xenograft (PDX) models of triple negative 445 
breast cancer included those derived from BRCA1-deficient tumours with BRCA1 446 
promoter hypermethylation and a frameshift mutation leading to a premature stop 447 
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(BRCA1.c2210delC). In line with previous observations in BRCA1-mutated tumours, 448 
BRCA1 c2210delC therapy resistant tumours had intragenic deletions that restore 449 
the BRCA1 open reading frame to restore BRCA1 expression and IR-induced foci 450 
formation of RAD51. Interestingly, demethylation of the BRCA1 promoter was shown 451 
to be the major mechanism of resistance in therapy resistant tumours derived from 452 
BRCA1 promoter hypermethylated tumours. BRCA1 gene fusions with other 453 
chromosome 17 genes also allowed the bypass of BRCA1 promoter 454 
hypermethylation to allow BRCA1 expression in a few drug-resistant tumours. 455 
Analysis of posttreatment tumours from individuals with BRCA1 promoter 456 
hypermethylation in pretreatment samples showed a significant decrease in BRCA1 457 
promoter methylation which correlated with a similar increase in BRCA1 mRNA. 458 
Taken together, data from these studies provide strong evidence of BRCA1 459 
restoration by multiple mechanisms, including BRCA1 promoter demethylation, as an 460 
important driver of PARP inhibitor and cisplatin resistance in BRCA1-deficient breast 461 
cancer. 462 
 463 
Though clinical examples of secondary BRCA1/2 mutations in PARP inhibitor-464 
resistant breast and other cancers remain few, more extensive data are available for 465 
secondary BRCA1/2 mutations in platinum-resistant cancers (Dhillon, et al. 2011; 466 
Norquist et al. 2011; Swisher et al. 2008). Data from cell line models and the limited 467 
clinical samples suggest that BRCA1/2-restored, platinum-resistant tumours have a 468 
high likelihood of being cross-resistant to PARP inhibitor. Additionally, secondary 469 
BRCA1/2 mutations resulting in PARP inhibitor and cisplatin resistance are likely 470 
driven by the convergence of at least three different factors: increased mutation rate 471 
due to exposure to genotoxic agents, the lack of error-free DNA repair and a 472 
selective advantage for BRCA1/2-restored cells when patients are treated with PARP 473 
inhibitors or platinum salts. 474 
 475 
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Several examples of BRCA1/2 restoration by means other than secondary mutation 476 
also exist. For example, Johnson et al showed that stabilization of a normally 477 
undetectable mutant BRCA1 protein can lead to PARP inhibitor resistance in 478 
rucaparib selected clones derived from the MDA-MB-436 breast cancer cell line, 479 
harboring a BRCA1.5396+1C>A splice donor site mutation (Johnson, et al. 2013). 480 
Expression of an HSP90-stabilized, carboxy-terminus truncated BRCA1 protein 481 
results in restoration of damage induced RAD51 foci formation and decreased PARP 482 
inhibitor induced chromosomal aberrations. Reduced 53BP1 expression was also 483 
observed in rucaparib resistant cells which may allow increased BRCA1-independent 484 
CtIP-mediated resection, though 53BP1 loss alone was not sufficient to render cells 485 
resistant to the PARP inhibitor. The combination of mutant protein stabilization and 486 
reduced 53BP1 expression was also observed in a clinical cisplatin-resistant ovarian 487 
cancer sample though response to PARP inhibitor is unknown.  488 
 489 
In another study, Wang et al demonstrated that breast cancer cell lines with 490 
mutations in the central large exon 11 of BRCA1 express the Δ11q splice variant 491 
show partial PARP inhibitor resistance, and strong ionizing radiation-induced BRCA1 492 
and RAD51 foci formation (Wang, et al. 2016a). Depletion of the Δ11q splice variant 493 
reduced foci formation and sensitized cells to PARP inhibitor and cisplatin. Moreover, 494 
five year overall survival in individuals with the exon 11 mutations was similar to 495 
those with wildtype BRCA1 and worse than those carrying mutations outside of exon 496 
11.  497 
 498 
Several groups have provided evidence for hypomorphic activity of two additional 499 
BRCA1 mutations that contribute to PARP inhibitor and cisplatin resistance (Drost, et 500 
al. 2011; Drost, et al. 2016; Powell 2016; Wang, et al. 2016b). The BRCA1.C61G 501 
mutation in the RING domain abolishes BRCA1 ubiquitin ligase activity, while still 502 
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promoting tumourigenesis. Importantly, mouse Brca1.C61G cells are not sensitive to 503 
PARP inhibition suggesting the mutant protein retains at least partial function. Drost 504 
et al also showed recently that a BRCA1 variant missing the RING domain (“RING-505 
less” BRCA1) can be detected in cells from a mouse model carrying the 506 
Brca1.185STOP mutation and in the human breast cancer cell line SUM1315MO2 507 
with the BRCA1.185delAG mutation (Drost et al. 2016). Importantly, expression of 508 
“RING-less” BRCA1 renders cells partially resistant to PARP inhibitor and cisplatin, 509 
suggesting its intact carboxy-terminus provides partial function. Moreover, Wang et al 510 
showed that PARP inhibitor and cisplatin resistant clones of the SUM1315MO2 cell 511 
line had increased expression of the “RING-less” BRCA1 variant that results from 512 
translation at an alternative start site (Wang et al. 2016b). Ectopic overexpression of 513 
this BRCA1 variant resulted in partial resistance to PARP inhibitor and cisplatin in 514 
vitro and in vivo. Interestingly, Drost et al did not observe increased expression of the 515 
“RING-less” BRCA1 consistently in cisplatin resistant clones. The existence of partial 516 
function mutants warrants a better understanding of how specific mutations impact 517 
response to PARP inhibitor, cisplatin and other therapies and the clinical 518 
management of BRCA-deficient breast and other types of cancers.  519 
 520 
5.2 Loss of 53BP1 expression 521 
BRCA1 and 53BP1 play important roles in choice of DSB repair by HR or NHEJ: 522 
BRCA1 promotes HR while 53BP1 tips the balance in favour of NHEJ. Several 523 
groups have shown that loss of the 53bp1 in a Brca1-null or Brca1Δexon11 mice 524 
rescues embryonic lethality observed in Brca1-deficient mice (Bouwman et al. 2010; 525 
Bunting et al. 2010; Cao, et al. 2009). Brca1/53bp1-deficient cells and mice also 526 
have restored growth, decreased chromosomal aberrations, increased RAD51 foci 527 
formation and at least partially restore HR relative to Brca1-deficient mice. 528 
Importantly, the loss of 53bp1 in Brca1-deficient mice renders them resistant to 529 
PARP inhibitor. Additionally, a subset of olaparib-resistant Brca1/P-glycoprotein-530 
Synthetic lethality and breast cancer       21 
 
deficient murine tumours had lost 53bp1 expression, while several others had 531 
heterogeneous expression (Jaspers, et al. 2013). Bouwman et al also found reduced 532 
53BP1 expression in clinical BRCA1/2-associated and triple negative breast cancers 533 
(Bouwman et al. 2010). Lower 53BP1 expression was correlated with lower 534 
metastasis free survival, presumably due to reduced response to therapy. Together 535 
these data suggested that 53BP1 loss in a BRCA1-deficient background is a 536 
mechanism of PARP inhibitor resistance in mice and humans. The prevalence of 537 
53BP1 loss in patients with BRCA1-associated and triple negative breast cancer 538 
remains to be determined.  539 
 540 
5.3 Replication fork protection  541 
Studies investigating the mechanisms that mediate replication fork stability in the 542 
absence of BRCA1 or BRCA2 have led to a number of additional mechanisms of 543 
drug resistance to be proposed. As discussed earlier, replication forks in BRCA1/2 544 
mutant cells are liable to degradation via MRE11 (Pathania et al. 2014; Schlacher et 545 
al. 2011; Schlacher et al. 2012). Chaudhuri et al recently found that that in Brca2 546 
mutant cells, loss of PTIP improved cell viability, protected HU-stalled replication 547 
forks from MRE11-mediated degradation and decreased genetic instability 548 
(Chaudhuri, et al. 2016). These effects were not caused by restoration of HR, but are 549 
best explained by PTIP’s role in localising MRE11 to replication forks; in the absence 550 
of PTIP, replication fork degradation via MRE11 was reduced, which in turn led to a 551 
reduction in replication fork degradation. Chaudhuri et al also found that BRCA1/2-552 
deficient cells with co-occurring PTIP defects also showed a reduced number of 553 
chromosomal abnormalities when exposed to either cisplatin or a PARP inhibitor, 554 
suggesting that these processes could influence BRCA1/2 mutant tumour cell 555 
response to therapy (Chaudhuri et al. 2016). Indeed, in a series of Brca2-deficient, 556 
PARP inhibitor resistant, mouse tumours, RAD51 foci formation was not restored but 557 
replication fork degradation after HU challenge was reduced, suggesting that HR 558 
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restoration was not the cause of drug resistance in this case, but that restoration of 559 
fork stability could be (Chaudhuri et al. 2016). Taken together, this data provide a 560 
case for assessing biomarkers of replication fork stability in clinical trials involving 561 
BRCA1/2 mutant cancer patients. 562 
 563 
5.4 PARP inhibitor resistance due to increased efflux 564 
Increased efflux of PARP inhibitor from cancer cells also contributes to PARP 565 
inhibitor resistance in the BRCA1/2 mutation context. Rottenberg et al showed that 566 
mammary tumours in Brca1/p53 double-mutant mice that are initially very responsive 567 
to olaparib eventually become resistant to the drug (Rottenberg, et al. 2008). PARP 568 
inhibitor resistance in these tumours is mediated by increased expression of P-569 
glycoprotein (Pgp) transporter genes Abcb1a and Abcb1b and can be reversed by 570 
inhibiting Pgp activity with tariquidar. Knock out of the Pgp Mdr 1a/b gene in a Brca1 571 
mutant background improved response of mammary tumours to PARP inhibitor, 572 
though they eventually became resistant due to other mechanisms (Jaspers et al. 573 
2013). Additionally, multidrug resistance, including to olaparib, observed in a Brca2-574 
mutated mouse model of mammary mesenchymal carcinosarcomas was, in part, due 575 
to increased Pgp expression (Jaspers, et al. 2015). Though increased efflux via Pgp 576 
transporter upregulation leads to PARP inhibitor resistance in Brca1 and Brca2 577 
mutant mouse models of breast cancer, it has yet to be reported in the clinic. 578 
 579 
6. BRCAness  580 
 581 
In addition to patients with germline BRCA1 or BRCA2 gene mutations (gBRCA), it 582 
seems very likely that significant numbers of cancer patients without gBRCA 583 
mutations have tumours that resemble, at the molecular and histological level, 584 
gBRCA mutant tumours, a phenomenon termed BRCAness (reviewed recently in 585 
(Lord and Ashworth 2016)). In some cases, these shared molecular features might 586 
also drive the same defect in HR that could lead to sensitivity to BRCA synthetic 587 
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lethal treatments such as PARP inhibitors.  588 
BRCAness might be driven by several different mechanisms. With the onset of large-589 
scale tumour sequencing, it is clear that in addition to germ-line BRCA gene 590 
mutations, a significant proportion of non-familial cancers have somatic alterations in 591 
BRCA1, BRCA2 or the growing number of genes associated with HR. For example, 592 
triple negative breast cancers, HGSOvCa, metastatic, castration-resistant prostate 593 
cancer and pancreatic ductal adenocarcinomas exhibit somatic alterations in BRCA1, 594 
BRCA2 or BRCAness genes such as ATM, ATR, BAP1, CDK12, CHK1, CHK2, the 595 
Fanconi anemia proteins (FANCA, C, D2, E, F), PALB2, NBN, WRN, the RAD51 596 
homologs RAD51B, C and D, MRE11A, BLM and BRIP1 (reviewed in (Lord and 597 
Ashworth 2016)). Many of these genes have been shown in pre-clinical models to 598 
cause PARP inhibitor sensitivity when dysfunctional (Bajrami, et al. 2014; Blazek, et 599 
al. 2011; Joshi, et al. 2014; McCabe, et al. 2006), extending the causative link 600 
between HR dysfunction and sensitivity to these drugs. 601 
There is also growing evidence for BRCAness in tumours that have a particular 602 
spectrum or pattern of mutations. One of the key observations made from the 603 
genomic profiling of tumours is the classification of tumours according to the type of 604 
mutations they possess, a mutational scar, rather than the specific genes that are 605 
mutated. In some instances, these mutational scars reflect the natural history of a 606 
tumour, and particularly the types of DNA damage and repair that have molded the 607 
genome over successive cell cycles. For example, BRCA1 and BRCA2 mutant 608 
tumours exhibit a mutational scar that appears to be caused by the elevated use of 609 
NHEJ, a DNA repair process that predominates in the absence of HR. For example, 610 
recent work from Nik-Zainal and colleagues, based on data from the whole-genome 611 
sequences of 560 breast tumours, confirmed the presence of three distinct genomic 612 
rearrangement signatures associated with loss of HR in tumours, each characterised 613 
by tandem DNA duplications or deletions; one of these signatures appears to be 614 
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associated with loss of BRCA1 function, the second being associated with defective 615 
BRCA1 or BRCA2, with the etiology of the third signature remaining largely unknown 616 
(Nik-Zainal, et al. 2016). The discovery of these genomic signatures in part reflects 617 
observations made in genetically engineered mouse cell lines with either Brca1 or 618 
Brca2 mutations, where the use of non-conservative forms of DNA repair such as 619 
NHEJ results in an elevated frequency of DNA deletions flanked by short, tandem 620 
DNA repeats at the break points of the deletion (Moynahan et al. 2001b; Tutt, et al. 621 
2001; Xia, et al. 2001). Similar mutational scars to those seen in gBRCA mutant 622 
tumours are also seen in non-gBRCA mutant tumours, and even in those without a 623 
detectable germline or somatic alteration in an HR gene, suggesting that similar DNA 624 
repair defects might be operating in these tumours. Importantly, there is now a 625 
growing body of evidence that suggests that the presence of such BRCAness 626 
mutational scars also correlates with clinical responses to HR targeting agents such 627 
as platinum salts and PARP inhibitors (Birkbak, et al. 2013), correlations which are 628 
driving the development of clinically applicable BRCAness mutational scar assays. 629 
Most of these assays use genome-wide DNA copy number profiling to estimate the 630 
extent of chromosomal rearrangements characteristic of an HR defect (Birkbak et al. 631 
2013). 632 
 633 
6. Extending the utility of the synthetic lethal paradigm 634 
It seems reasonable to question whether synthetic lethality as a concept might have 635 
a wider applicability in the search for optimised treatments for breast cancer. The 636 
progress in the molecular profiling of breast tumours means that there is now a 637 
working list of driver gene defects in the disease that in principle could be targeted 638 
with a synthetic lethal approach. For example, many of the tumour suppressor gene 639 
defects that recurrently occur in breast cancer, such as TP53, PTEN and RB1 might 640 
be amenable to synthetic lethal approaches and already a number of candidate 641 
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synthetic lethal targets for these genes have been identified (Edgar, et al. 2005; 642 
Emerling, et al. 2013; Gordon and Du 2011; Mendes-Pereira, et al. 2012; Mereniuk, 643 
et al. 2013; Morandell, et al. 2013; Origanti, et al. 2013; Reaper, et al. 2011). Many of 644 
the efforts to identify synthetic lethal interactions that are relevant to breast cancer 645 
have been driven by advances in functional genomic approaches such as RNA 646 
interference screening and more recently CRISPR based screens (Gilbert, et al. 647 
2014; Morgens, et al. 2016; Wang, et al. 2015). The synthetic lethal approach might 648 
also be applied to target relatively common oncogene amplification events in breast 649 
cancer such as MYC amplification, which is present in over 22% of all breast tumours 650 
(Cerami, et al. 2012; Ciriello, et al. 2015; Gao, et al. 2013). MYC encodes a 651 
transcription factor, which might be challenging to directly target with drug-like small 652 
molecules, and so employing synthetic lethal strategies to targeting MYC 653 
amplification seems a reasonable approach. Already synthetic lethal interactions 654 
between MYC and the DR5 death receptor pathway (Wang, et al. 2004) or inhibition 655 
of the splicesome in MYC-dependent breast tumours have been identified (Hsu, et al. 656 
2015). This latter observation might be explained by an increased dependency in 657 
MYC amplified tumours upon pre-mRNA processing (Hsu et al. 2015).   658 
 659 
Whilst there are clearly opportunities to more widely exploit the synthetic lethal 660 
concept in breast cancer, there are also clear challenges. For a synthetic lethal effect 661 
to be clinically actionable and to have significant utility, there are certain qualities the 662 
synthetic lethal relationship must exhibit, many of which are common to all ideal 663 
therapeutic approaches, synthetic lethal or not. Firstly, the therapeutic window 664 
between tumour and normal cell inhibition/toxicity achieved with the synthetic lethal 665 
target must be profound. Secondly, ideal synthetic lethal effects must be highly 666 
penetrant – i.e. the presence of the predictive biomarker (e.g. a mutation in a breast 667 
cancer driver gene) must be highly predictive of sensitivity to inhibition of the 668 
synthetic lethal target; if this is not the case then a novel synthetic lethal treatment 669 
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might only work in a minority of patients or a minority of tumour cell clones within an 670 
individual. Thirdly, ideal synthetic lethal interactions must be relatively resilient to 671 
additional molecular changes that might reverse the synthetic lethal effect; this is 672 
critical if clinical synthetic lethal effects are to be effective in breast tumours, whose 673 
inherent molecular heterogeneity and ability to evolve and survive in the face of 674 
negative selective pressure is well documented (Alizadeh, et al. 2015; Brooks, et al. 675 
2015). Despite advances in the ability to identify synthetic lethal effects in breast 676 
tumour cells, somewhat less attention is often given to whether these effects also 677 
fulfill these ideal criteria. 678 
 679 
One concept that might gain further scrutiny in the future is the idea of exploiting 680 
combinations of different synthetic lethal effects in the same tumour, each of which 681 
focuses on a different breast cancer driver gene or phenotype. For example, in triple 682 
negative breast cancers with germline or somatic BRCA gene mutations, TP53 683 
mutations also co-occur. It seems reasonable to suggest that a drug combination 684 
strategy that involves a PARP inhibitor (to synthetically lethal target the BRCA gene 685 
defect), used alongside a TP53 synthetic lethal therapy, might be more effective than 686 
PARP inhibitor monotherapy which might be limited by the emergence of secondary 687 
mutant BRCA1/2 alleles. This idea of targeting multiple co-occurring driver mutations 688 
in the same tumour might be most effective when mutations that occur early on in the 689 
disease process, and so are more likely present in the majority of subclones in a 690 
tumour, are selected.  691 
 692 
7. Conclusions and future prospects 693 
The cloning of BRCA1 and BRCA2 stimulated a large body of work, from many 694 
investigators, that ultimately resulted in the first clinically approved treatment for a 695 
genetically defined cancer syndrome. Whilst this work provides a very compelling 696 
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narrative that illustrates the impact pre-clinical and clinical research can have, 697 
several important questions still remain. Some of these pertain directly to the use of 698 
PARP inhibitors whilst others are also relevant to the treatment of cancer in general. 699 
For example, although olaparib has been approved for use as a maintenance 700 
therapy after platinum treatment in HGSOv cancer, a role for first line PARP inhibitor 701 
treatment in BRCA1 or BRCA2 mutant patients, or those with BRCAness, remains to 702 
be established. There is also very little understood about what might constitute the 703 
optimal drug combination strategies involving PARP inhibitors or how patients with 704 
PARP inhibitor resistance might best be treated. It seems reasonable to suggest that 705 
some of the answers to these questions will come from clinical studies but also will 706 
be informed by pre-clinical research and a continued focus on the molecular biology 707 
of the BRCA1 and BRCA2 genes. More generally, the wider clinical applicability of 708 
the synthetic lethal concept is still not established, although it is hoped the continued 709 
pre-clinical research activity in this area will ultimately lead to further clinical trials 710 
drug approvals that deliver more effective treatments of cancer patients.  711 
 712 
 713 
 714 
 715 
 716 
  717 
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Figure and Table legends 728 
Figure 1. Oncogene addiction and synthetic lethality. Oncogene and tumour 729 
suppressor gene mutations drive the oncogenic process. As well s driving the 730 
oncogenic process, alterations in oncogenes and tumour suppressor also impart 731 
upon tumour cells a distinct set of genetic dependencies not present in normal cells, 732 
known as oncogene addictions, non-oncogene addictions and synthetic lethal 733 
effects. A. Oncogene addiction is the situation where a tumour cell becomes totally 734 
dependent on the activity of a mutated gene (Gene A is shown as an example). An 735 
analogous scenario, known as non-oncogene addiction exists when tumour cells with 736 
an alteration in an oncogene A, become addicted to the activity of a non-oncogene, 737 
B. B. Synthetic lethality is a scenario where loss of either gene A or gene B function 738 
is tolerated but simultaneous loss of both genes is not. In normal cells inhibition of 739 
either A or B does not result in cell death. In tumour cells where gene B is rendered 740 
dysfunctional (for example by mutation) inhibition of gene A results in cell death.  741 
 742 
 Figure 2. DNA lesions causing replication fork collapse. A working model 743 
of the DNA damage response (DDR) to replication fork stalling agents is shown. 744 
Drug-like PARP inhibitors trap PARP on DNA. Likewise, Topoisomerase poisons trap 745 
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topoisomerase enzymes on DNA. Platinum salts cause DNA cross-links. Each of 746 
these events stalls the progression of replication forks in S phase. Stalled forks often 747 
collapse, forming DNA double strand DNA breaks. DSBs in this setting are often 748 
cytotoxic if not repaired. The normal DNA repair process, homologous 749 
recombination, is controlled by BRCA1 and BRCA2. BRCA1 function is required for 750 
the processing of DNA ends prior to repair, a process known as end resection. Once 751 
end resection is complete, BRCA2 localises the key DNA recombinase enzyme, 752 
RAD51, to DNA at the site of DNA damage. The binding of RAD51 to DNA allows 753 
damaged DNA to invade an intact DNA double helix with homologous DNA 754 
sequence to that at the site of DNA damage (often in the sister chromatid), which is 755 
used as a template upon which to synthesise new DNA as part of the DNA repair 756 
process. In the absence of functional BRCA1 and BRCA2, cells either fail to 757 
effectively repair DNA (which can lead to apoptosis), or to utilise orthogonal DNA 758 
repair processes such as Non Homologous End Joining, which increase the 759 
frequency of complex DNA rearrangements, events that ultimately impair the fitness 760 
of cells. 761 
 762 
Figure 3: Mechanisms of PARP inhibitor resistance in BRCA1/2-763 
associated cancers. Loss of PARP inhibitor resistance in BRCA1/2 mutated 764 
cancers can occur via (1) restoration of BRCA1/2 function and HR by secondary 765 
intragenic BRCA1/2 mutations, expression of hypomorphic BRCA1 alleles, 766 
stabilization of mutant BRCA proteins and demethylation of the BRCA1 promoter, (2) 767 
restoration of HR as a result of relief from 53BP1 mediated block on end-resection 768 
(only in BRCA1 mutant tumour cells), (3) protection of replication forks, from MRE11-769 
mediated degradation, due to loss of PTIP, CHD4 or PARP1 expression and (4) 770 
increased efflux of PARP inhibitor from cancer cells as a result of increased P-771 
glycoprotein expression. 772 
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